About Apotex

We are a Canadian pharmaceutical company with global presence that produces affordable and high-quality medicines.

Apotex^® was founded in 1974 by Dr. Barry Sherman. From our humble origins when we only had two employees, we’ve grown to currently employ over 8,000 people worldwide in the areas of manufacturing, research and development, and business operations. Through vertical integration, the Apotex^® Group of Companies is comprised of research and development, manufacture of active pharmaceutical ingredients and finished product.

With presence in over 115 countries and operations in more than 45, among which Canada, the United States, Mexico and India stand out, where we continue to invest. Our footprint includes a wide network of affiliates, distributors and strategic alliances.

Globally, we produce approximately 25 billion doses each year, which are used to fill 89 million prescriptions (one out of five), in Canada alone.

We started operations in Mexico and Central America in 1996, consolidating ourselves in the Latin American market as an affordable and quality option. We have a finished product plant, research and development laboratories, as well as pharmachemical plants in Mexico for the manufacture of active pharmaceutical ingredients (API), which allow us to have a presence in the main sale points of the country. We continue to expand our scope for health improvement, having three subsidiaries in Central America: Panama, Costa Rica and Nicaragua, and a network of distributors that allow us to offer a Canadian quality option in Central America, South America, and the Caribbean.

In the past five years, we have brought over 20 prescription drugs to the world market and 30 to Latin America, once the patent had expired. As a result of this, both patients and health institutions have, globally, saved approximately $4 trillion dollars. In Canada, nearly $19 trillion dollars have been saved in total through the timely release of medicines.

We are the largest Research and Development investor in Canada, compared to any pharmaceutical company. In the last 10 years, we have invested $1 trillion CAD in Research and Development, foreseeing an additional investment of $2 trillion CAD for the next 10 years.

Furthermore, we have the most complete and state-of-the-art laboratories of the industry in Canada, and more than 1,100 active projects accounting for over 500 molecules (generic and innovative) in 50 countries.